A combination of anti-WNT2 and anti-PD-1 monoclonal antibodies has been found to enhance anti-tumor T cell responses and improve the effectiveness of anti-PD-1 therapy in syngeneic mouse models of OSCC and CRC by increasing active DCs. This evidence concerns the gene WNT2 and neoplasm.